IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion., PMID:40371594
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors., PMID:40310569
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia., PMID:40229904
Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment., PMID:39694705
IL1RAP Blockade With a Monoclonal Antibody Reduces Cardiac Inflammation and Preserves Heart Function in Viral and Autoimmune Myocarditis., PMID:39513273
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer., PMID:39385434
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells., PMID:39143574
Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis., PMID:38594058
Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation., PMID:38563353
Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma., PMID:37812652
Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk., PMID:37498674
Breast cancer associated CD169+ macrophages possess broad immunosuppressive functions but enhance antibody secretion by activated B cells., PMID:37404831
Circulating neutrophils activated by cancer cells and M2 macrophages promote gastric cancer progression during PD-1 antibody-based immunotherapy., PMID:37333017
IL-1RAP, a Key Therapeutic Target in Cancer., PMID:36499246
Bacterial production and biophysical characterization of a hard-to-fold scFv against myeloid leukemia cell surface marker, IL-1RAP., PMID:36435922
Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy., PMID:36036818
Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor., PMID:35003094
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours., PMID:34903842
Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33., PMID:34408465
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma., PMID:34021002
Identification and Targeting of Thomsen-Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies., PMID:33519209
Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis., PMID:33452871
Structure-based Development of Human Interleukin-1β-Specific Antibody That Simultaneously Inhibits Binding to Both IL-1RI and IL-1RAcP., PMID:33359099
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML., PMID:33085758
The Role of SNPs in IL1RL1 and IL1RAP Genes in Age-related Macular Degeneration Development and Treatment Efficacy., PMID:32871771
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease., PMID:31427775
[IL-1RAP as a candidate for CAR T-cells immunotherapy]., PMID:31274074
CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells., PMID:30514753
Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer., PMID:30257318
IL1RAP potentiates multiple oncogenic signaling pathways in AML., PMID:29773641
Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia., PMID:29772458
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy., PMID:28115015
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models., PMID:27621309
Targeting microglia for the treatment of Alzheimer's Disease., PMID:27100611
Novel strategies for targeting innate immune responses to influenza., PMID:26813341
[Cloning of VH and VL Gene of Human anti-IL1RAP McAb and Construction of Recombinant Chimeric Receptor]., PMID:26524021
[Preparation and Assessment of IL1RAP Monoclonal Antibody]., PMID:26314426
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia., PMID:26261316
Mechanisms of splicing-dependent trans-synaptic adhesion by PTPδ-IL1RAPL1/IL-1RAcP for synaptic differentiation., PMID:25908590
[Construction of hybridoma cells with IL1RAP as a new marker for leukemia stem cells and detection of its monoclonal antibody]., PMID:24370017
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP., PMID:23479569
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein., PMID:20805474
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33., PMID:18450470
IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells., PMID:18003919
Human hepatitis B viral e antigen interacts with cellular interleukin-1 receptor accessory protein and triggers interleukin-1 response., PMID:16973626
Expression of mRNAs encoding receptors that mediate stress signals in gonadotropin-releasing hormone neurons of the mouse., PMID:16721036
Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist., PMID:15986350
Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs., PMID:14734551
Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis., PMID:14558102
Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells., PMID:12421347
For research use only. Not for human or drug use.
